Published online Nov 15, 2026. doi: 10.4251/wjgo.123962
Revised: July 22, 2026
Accepted: September 1, 2026
Published online: November 15, 2026
Processing time: 156 Days and 10.8 Hours
The proportion of patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is as high as 85.69% among HCC patients in China. Current anti-HBV drugs include nucleos(t)ide analogs (NAs) and interferon (IFN).
To compare the impact of NAs and IFN therapy on the occurrence of HCC in patients at high risk of HBV-related HCC.
We enrolled 368 patients with high risk of HBV-related HCC, and 120 received subcutaneous injections of IFN, with or without NAs, constituting the IFN group. The remaining 248 patients were assigned to the NAs group, and received treatment with NAs alone.
For patients with a high risk of HBV-related HCC, after a 5-year treatment period, HCC incidence in the IFN group was 2.54%, while the NAs group showed a significantly higher incidence of 25.74% (P < 0.001). After propensity score matching, HCC incidence in the IFN and NAs groups was 2.94% and 22.0%, respectively (P < 0.001).
IFN-based therapy, compared with NAs, significantly reduced the risk of HCC in patients with high risk of HBV-related HCC.
Core Tip: Based on this observational study, we compared the incidence of hepatocellular carcinoma (HCC) in high-risk hepatitis B virus-related HCC patients receiving interferon vs nucleoside/nucleotide analogues. For hepatitis B virus-infected individuals with high-risk factors for HCC, interferon therapy before progression to decompensated cirrhosis helps reduce the risk of HCC.
- Citation: Hao M, Liu CR, Zhang M, Zhou XQ, Jiang ZC, Gao XH, Zhang X, Wang WJ, Wang YK, Jia XL, Li YP, Dang SS. Interferon therapy reduces incidence of hepatocellular carcinoma in patients with high risk of hepatitis B virus-related hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(11): 123962
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/123962.htm
- DOI: https://dx.doi.org/10.4251/wjgo.123962
Recently, the disease burden of hepatocellular carcinoma (HCC) has surged in China, with approximately 410000 new cases and 391000 deaths in 2020, accounting for nearly half of the global burden[1]. The proportion of patients with hepatitis B virus (HBV)-related HCC is as high as 85.69% among HCC patients in China[2]. Although the popularization of hepatitis B vaccination has significantly reduced the number of new hepatitis B patients each year, there remains a large number of individuals with chronic hepatitis B (CHB) in China[3]. Most newly diagnosed cases of HCC are at an advanced stage, specifically Barcelona Clinic Liver Cancer stage C[4]. Therefore, early identification of HBV-related HCC high-risk groups coupled with individualized treatment and regular monitoring are important to reduce the incidence and burden of HCC.
Antiviral therapy for CHB reduces the risk of developing HCC by maximizing suppression of HBV replication and improving liver histopathology[5]. The Asia Pacific Association for the Study of Liver Diseases 2017 guidelines state that long-term and effective antiviral therapy in patients with CHB can be used as a secondary preventive measure for HBV-related HCC[6]. Current antiviral drugs include nucleos(t)ide analogs (NAs) and interferon (IFN)[7]. IFN-based treatment is superior to NA therapy in reducing HBV-related HCC in CHB patients[8]. However, several studies have shown that patients with CHB remain at risk of developing HCC after long-term antiviral therapy, and antiviral therapy can reduce but not eliminate the occurrence of HCC[9]. Several other studies have demonstrated that patients with high-risk factors for HCC, such as liver cirrhosis and a family history of HCC, have a significantly elevated risk of developing HCC compared with those with a common HBV infection[10-14]. For people at high-risk of HBV-related HCC, the application of IFN therapy is crucial to reduce the incidence of HCC. Therefore, in this study, we aimed to compare the effects of NAs and IFN on the risk of HCC in patients with high risk of HBV-related HCC. Additionally, the existing risk prediction models of HCC were validated by an external cohort and the main factors affecting the occurrence of HCC in this population were analyzed by logistic regression.
This study collected patients with CHB who visited the Department of Infectious Diseases, the Second Affiliated Hospital of Xi’an Jiaotong University, Ankang Central Hospital, and the Affiliated Hospital of Yanan University from July 2011 to May 2023 in China. This study complied with clinical practice and the Declaration of Helsinki and was approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University, approval No. 2022-051. Written informed consent was waived by the Ethics Committee because this was a retrospective study using existing medical records and de-identified data, which involved no more than minimal risk to participants, and it was impracticable to obtain consent from all eligible individuals due to the large sample size and the difficulty of contacting patients retrospectively.
Inclusion criteria: (1) 18-65 years of age, regardless of gender; (2) CHB patients positive for hepatitis B surface antigen for > 6 months; and (3) High risk of HBV-related HCC (patients with any one of the following): Male ≥ 40 years, female ≥ 50 years; family history of HCC; alpha-fetoprotein (AFP) ≥ 7.0 ng/mL; liver nodules detected on imaging (defined as any focal lesion ≥ 5 mm detected on ultrasound, computed tomography, or magnetic resonance imaging, regardless of pathological nature); and compensated cirrhosis due to HBV (in accordance with the American Association for the Study of Liver Diseases 2018 hepatitis B guidance)[12].
Exclusion criteria: (1) Decompensated cirrhosis; (2) Study began at the time of diagnosis or within 6 months of being diagnosed with liver cancer or other systemic malignant tumors; (3) Hepatitis A virus, hepatitis C virus, hepatitis D virus, human immunodeficiency virus infection, or autoimmune hepatitis; and (4) Patients with severe cardiac, renal, and pulmonary insufficiency.
This was a multicenter retrospective study. Patients were assigned to the IFN group and NAs group according to their antiviral regimen. The IFN group received subcutaneous injections of peginterferon α-2a or peginterferon α-2b (180 μg/week), with or without NAs, for a total course of ≥ 24 weeks, constituting the IFN group. After completion of the 24-week IFN course, patients either continued IFN therapy (if clinically indicated) or switched to NAs maintenance therapy, based on the treating physician's clinical judgment. The duration of IFN treatment varied according to individual patient response and tolerability. Patients in the NAs group were treated with NAs alone. The NAs used in this study included entecavir (0.5 mg daily), tenofovir disoproxil fumarate (300 mg daily), lamivudine (300 mg daily) and tenofovir alafenamide (25 mg daily), etc, with the specific agent chosen according to the treating physician's discretion and patient characteristics.
The start of follow-up (time zero) was defined as the date of treatment initiation (first dose of IFN or first prescription of NAs) for all patients. For patients who had received prior antiviral therapy before enrollment, time zero was set as the date of enrollment into this study when the current treatment regimen was initiated. Patients who developed HCC within the first 6 months of follow-up were excluded to avoid reverse causality (as specified in the exclusion criteria). The endpoint was the occurrence of HCC. The design and patients enrolled in this study is shown in Figure 1.
Study assessments were based on the patients’ clinical history, laboratory findings, and imaging studies. The measures included clinical data at the start of and during treatment, including history of CHB, previous medication, family history of HCC, comorbidities (diabetes, fatty liver, etc.), and alcohol intake. Laboratory tests included white blood cell count, platelet count, alanine aminotransferase, aspartate aminotransferase, total bilirubin, albumin, HBV DNA, hepatitis B surface antigen, HBV e antigen, and AFP. Imaging examinations included liver B-ultrasound, computed tomography, and magnetic resonance imaging. Laboratory tests were performed at baseline and every 3-6 months during follow-up. Imaging examinations were performed at baseline and every 6-12 months, or more frequently if clinically indicated. The diagnosis of HCC is based on the “Diagnosis and Treatment Guidelines for Primary Liver Cancer (2019 Edition)” of China.
In this study, the published Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV (REAL-B) model and the age-male-ALBI-platelets (aMAP) model were used to assess the risk of HCC in patients[15,16]. The REAL-B model incorporates the following variables: Age, sex, alcohol consumption, liver cirrhosis, platelet count, diabetes, and AFP[15]. The aMAP model incorporates: Age, sex, albumin-bilirubin grade, and platelet count[16]. Among them, the REAL-B model score 0-3 was classified as low risk, 4-7 as medium risk, and 8-13 as high risk. In the aMAP model, < 50 was classified as low risk, 50-60 as medium risk, and > 60 as high risk.
All patients who participated in this study were included in the final analysis. Statistical analysis was performed using SPSS version 27.0 and R version 4.3.3. The measurement data that conformed to normal distribution were expressed as the mean ± SD, the non-normally distributed data were expressed as the median and interquartile range, and the enumeration data were expressed as the rate. Propensity score matching (PSM) analysis was used to eliminate the influence of selection bias and patient baseline characteristics. By adjusting the baseline difference between the two groups to balance the influence of confounding factors, the specific matching ratio was 1:2 (IFN:NAs), with a caliper of 0.2 times the standard deviation of the propensity score. This resulted in 71 patients in the IFN group and 145 in the NAs group (actual matching ratio of 1:2.04, which approximates the intended 1:2 ratio). One-way analysis of variance was used to compare the means of measurement data with a normal distribution among multiple groups, and a nonparametric test was used to compare the means of measurement data with a non-normal distribution or unequal variance between groups. The Kaplan-Meier method was used to calculate the cumulative incidence of HCC after follow-up in both groups, and the last follow-up data were used for patients without HCC. Differences between groups were compared using the log-rank test. Univariate and multivariate Cox regression analyses were performed to assess the magnitude and significance of factors associated with hepatocarcinogenesis. All statistical tests were two-sided and P < 0.05 was considered statistically significant. This retrospective cohort study was reported in accordance with the STROBE statement.
Figure 1 presents the flow chart illustrating the selection process for participants in this study. Patients without high-risk factors for HCC, decompensated liver cirrhosis, combined, infection, self-discontinuation or loss to follow-up and patients who were diagnosed with HCC at the beginning were excluded from the analysis. After applying these exclusion criteria, this study finally included 368 patients, including 120 in the IFN group and 248 in the NAs group. Among the 120 patients in the IFN group, 39 (32.5%) received IFN monotherapy and 81 (67.5%) received IFN plus NAs combination therapy. The baseline characteristics of patients before and after PSM are shown in Table 1. After PSM, 216 patients were obtained, including 71 in the IFN group and 145 in the NAs group. There was no significant difference in baseline characteristics between the IFN and NAs groups (P > 0.05). It is important to acknowledge that before PSM, the NAs group had a higher proportion of patients with cirrhosis, elevated AFP, HBV e antigen positivity, and higher HBV DNA levels, indicating greater baseline disease severity. While PSM successfully balanced the measured covariates, residual confounding from unmeasured factors cannot be completely excluded. Nonetheless, the consistent protective effect of IFN observed across multiple sensitivity analyses supports the robustness of our findings.
| Character | Before PSM | After PSM | ||||||
| IFN group | NAs group | P value | SMD | IFN group | NAs group | P value | SMD | |
| Sex | - | - | 0.56 | - | - | - | 0.219 | - |
| Female | 29 (24.17) | 67 (27.02) | -0.067 | 15 (21.13) | 42 (28.97) | - | -0.175 | |
| Male | 91 (75.83) | 181 (72.98) | 0.067 | 56 (78.87) | 103 (71.03) | - | 0.175 | |
| Age | - | - | 0.359 | - | - | - | 0.68 | - |
| Male < 40 years or female < 50 years | 45 (37.50) | 81 (32.66) | - | 0.1 | 29 (40.85) | 55 (37.93) | - | 0.083 |
| Male ≥ 40 years or female ≥ 50 years | 75 (62.50) | 167 (67.34) | - | -0.1 | 42 (59.15) | 90 (62.07) | - | -0.083 |
| Family history of HCC | - | - | 0.005 | - | - | - | 0.622 | - |
| No | 103 (85.83) | 180 (72.58) | 0.38 | 56 (78.87) | 110 (75.86) | - | 0.058 | |
| Yes | 17 (14.17) | 68 (27.42) | -0.38 | 15 (21.13) | 35 (24.14) | - | -0.058 | |
| Liver cirrhosis | < 0.001 | - | - | - | 0.267 | - | ||
| Non-cirrhosis | 80 (66.67) | 103 (41.53) | - | 0.533 | 39 (54.93) | 68 (46.90) | - | 0.164 |
| Compensatory cirrhosis | 40 (33.33) | 145 (58.47) | - | -0.533 | 32 (45.07) | 77 (53.10) | - | -0.164 |
| Alpha-fetoprotein ≥ 7.0 ng/mL | - | - | < 0.001 | - | - | - | 0.288 | - |
| No | 101 (84.17) | 127 (51.21) | 0.903 | 53 (74.65) | 98 (67.59) | - | 0.144 | |
| Yes | 19 (15.83) | 121 (48.79) | -0.903 | 18 (25.35) | 47 (32.41) | - | -0.144 | |
| Liver nodules detected on imaging | - | - | 0.939 | - | - | - | 0.536 | - |
| No | 89 (74.17) | 183 (73.79) | - | 0.009 | 57 (80.28) | 111 (76.55) | - | 0.118 |
| Yes | 31 (25.83) | 65 (26.21) | - | -0.009 | 14 (19.72) | 34 (23.45) | - | -0.118 |
| Diabetes | - | - | 0.012 | - | - | - | 1 | - |
| No | 115 (95.83) | 217 (87.50) | - | 0.417 | 66 (92.96) | 136 (93.79) | - | -0.04 |
| Yes | 5 (4.17) | 31 (12.50) | - | -0.417 | 5 (7.04) | 9 (6.21) | - | 0.04 |
| Alcohol intake | - | - | 0.304 | - | - | - | 0.536 | - |
| No | 94 (78.33) | 182 (73.39) | 0.12 | 57 (80.28) | 111 (76.55) | - | 0.118 | |
| Yes | 26 (21.67) | 66 (26.61) | -0.12 | 14 (19.72) | 34 (23.45) | - | -0.118 | |
| Fatty liver | - | - | 0.823 | - | - | - | 0.633 | - |
| No | 105 (87.50) | 219 (88.31) | - | -0.024 | 60 (84.51) | 126 (86.90) | - | -0.078 |
| Yes | 15 (12.50) | 29 (11.69) | - | 0.024 | 11 (15.49) | 19 (13.10) | - | 0.078 |
| Platelet count (× 109/L) | 174 | 134.5 | < 0.001 | 0.826 | 163 | 149 | 0.103 | 0.252 |
| (146.00, 209.25) | (89.00, 177.25) | (139.00, 197.50) | (108.00, 190.00) | |||||
| HBsAg (IU/mL) | 378.49 | 1440.72 | < 0.001 | -1.043 | 495.81 | 818.42 | 0.088 | -0.262 |
| (87.61, 1013.48) | (559.95, 3118.72) | (157.23, 1409.65) | (425.93, 2236.81) | |||||
| HBeAg | - | - | < 0.001 | - | - | - | 0.245 | - |
| Negative | 100 (83.33) | 133 (53.63) | 0.797 | 53 (74.65) | 97 (66.90) | - | 0.16 | |
| Positive | 20 (16.67) | 115 (46.37) | -0.797 | 18 (25.35) | 48 (33.10) | - | -0.16 | |
| HBV DNA (lg IU/mL) | 0.00 (0.00, 2.01) | 2.90 (0.00, 5.30) | < 0.001 | -1.045 | 0.00 (0.00, 2.43) | 1.86 (0.00, 3.69) | 0.081 | -0.236 |
At the end of the 5-year follow-up period, a significant disparity in the occurrence of HCC was observed between patients in the IFN and NAs groups. Among patients with a high risk of HBV-related HCC, after 5 years of treatment, the cumulative incidence of HCC in the IFN group remained at 2.54%, while the NAs group experienced a significantly higher cumulative incidence of 25.74% (P < 0.001) (Figure 2A). After PSM, 32 patients developed HCC during the 5-year follow-up period, including two in the IFN group and 30 in the NAs group. After PSM, the 5-year cumulative incidence of HCC in the IFN and NAs groups was 2.94% and 22.0%, respectively. There was a significant difference in the 5-year cumulative incidence of HCC between the two groups (P < 0.001) (Figure 2B).
Subgroup analysis based on five risk factors and whether antiviral therapy was first taken showed that male ≥ 40 years old or female ≥ 50 years old, no family history of HCC, with or without cirrhosis, no elevated AFP, no liver nodular, and prior antiviral therapy were significant differences in HCC occurrence after NAs treatment and IFN treatment (P < 0.05). However, the interaction between subgroups was not obvious (P < 0.05) (Figure 3).
Univariate Cox regression analysis was performed on the factors that may affect the occurrence of HCC in patients with high-risk of HBV-related HCC. Age, family history of HCC, antiviral regimen, cirrhosis, and platelet count were correlated with the occurrence of HCC in patients with high risk of HBV-related HCC (P < 0.05). Multivariate Cox regression analysis suggested that male ≥ 40 years or female ≥ 50 years, and family history of HCC and cirrhosis were independent risk factors for HCC (P < 0.05). IFN treatment was an effective protective factor in patients with HCC (P < 0.001, hazard ratio = 0.12, 95% confidence interval: 0.04-0.39) (Table 2).
| Character | Univariate Cox regression | Multifactor Cox regression | ||
| P value | HR (95%CI) | P value | HR (95%CI) | |
| Sex | ||||
| Male | - | 1.00 (reference) | - | - |
| Female | 0.073 | 1.77 (0.95–3.30) | - | - |
| Age | ||||
| Male < 40 years or female < 50 years | - | 1.00 (reference) | - | 1.00 (reference) |
| Male ≥ 40 years or female ≥ 50 years | < 0.001 | 3.43 (1.70-6.92) | 0.005 | 2.76 (1.35-5.61) |
| Family history of HCC | ||||
| No | - | 1.00 (reference) | - | 1.00 (reference) |
| Yes | < 0.001 | 2.32 (1.43-3.75) | 0.022 | 1.76 (1.09-2.86) |
| Liver cirrhosis | ||||
| Non-cirrhosis | - | 1.00 (reference) | - | 1.00 (reference) |
| Compensatory cirrhosis | < 0.001 | 3.91 (2.21-6.93) | 0.009 | 2.27 (1.23-4.19) |
| -fetoprotein ≥ 7.0 ng/mL | ||||
| No | - | 1.00 (reference) | - | - |
| Yes | 0.748 | 1.08 (0.66-1.78) | ||
| Liver nodules detected on imaging | ||||
| No | - | 1.00 (reference) | - | - |
| Yes | 0.389 | 1.26 (0.75-2.12) | - | - |
| Diabetes | ||||
| No | - | 1.00 (reference) | - | - |
| Yes | 0.216 | 1.56 (0.77-3.14) | - | - |
| Alcohol intake | ||||
| No | - | 1.00 (reference) | - | - |
| Yes | 0.728 | 1.10 (0.65-1.86) | - | - |
| Fatty liver | ||||
| No | - | 1.00 (reference) | - | - |
| Yes | 0.995 | 0.00 (0.00-infinity) | - | - |
| Antiviral therapy | ||||
| NAs treatment | 1.00 (reference) | 1.00 (reference) | ||
| Peg IFN-α treated with NAs alone or in combination | < 0.001 | 0.08 (0.02-0.25) | < 0.001 | 0.12 (0.04-0.39) |
| White blood cell count (× 109/L) | 0.835 | 0.98 (0.85-1.14) | - | - |
| Platelet count (× 109/L) | < 0.001 | 0.99 (0.99-0.99) | 0.279 | 1.00 (0.99-1.00) |
| Glutamic-pyruvic transaminase (IU/L) | 0.518 | 1.00 (1.00-1.01) | - | - |
| Glutamic oxalacetic transaminase (IU/L) | 0.213 | 1.00 (1.00-1.01) | - | - |
| Albumin (g/L) | 0.576 | 1.01 (0.96-1.07) | - | - |
| Total bilirubin (μmol/L) | 0.491 | 1.01 (0.98-1.04) | - | - |
| Alkaline phosphatase (IU/L) | 0.391 | 1.00 (1.00-1.01) | - | - |
| Glutamyltranspeptidase (U/L) | 0.856 | 1.00 (1.00-1.00) | - | - |
| HBsAg (IU/mL) | 0.131 | 1.00 (1.00-1.00) | - | - |
| HBV DNA (lg IU/mL) | 0.477 | 0.97 (0.88-1.06) | - | - |
| HBeAg | ||||
| Negative | - | 1.00 (reference) | - | - |
| Positive | 0.410 | 0.81 (0.48-1.35) | - | - |
| Abdominal lymph node enlargement | ||||
| No | - | 1.00 (reference) | - | - |
| Yes | 0.610 | 1.30 (0.47-3.57) | - | - |
The REAL-B and aMAP models were used to evaluate HCC risk stratification before and after treatment in the IFN and NAs groups (Figure 4). According to the REAL-B model prediction and evaluation, after treatment, the number of low-risk HCC patients in the IFN group increased by 15, while the number of low-risk patients in the NAs group increased by 62, and the number of high-risk patients decreased by 39. The overall risk stratification of HCC in the two groups after treatment decreased significantly compared with before (P < 0.05). After treatment, in the IFN group evaluated by the aMAP model, the number of medium-risk HCC patients increased by 10, and the number of low-risk patients decreased by 10. There was no significant difference in the overall HCC risk stratification in the IFN group before and after treatment (P = 0.141). Compared with before treatment, the number of high-risk HCC patients in the NAs group increased by 13, the number of medium-risk patients increased by 18, and the number of low-risk patients decreased by 31. Compared with before treatment, the overall risk stratification of HCC in the NAs group increased after treatment (P = 0.002).
In this observational study, we compared the risk of HCC after IFN and NAs therapy in patients at high risk for HBV-related HCC. The results consistently indicated that the cumulative incidence of HCC was lower in the IFN than NAs group, regardless of whether PSM was performed. IFN is known to possess multiple beneficial effects, including antiviral, immunoregulatory, and antitumor properties[17-19]. Previous studies have confirmed that it can significantly reduce the occurrence of HCC in patients with CHB. A study conducted in Taiwan involving 330 CHB patients over 5 years found that the risk of HCC was lower in CHB patients treated with Peg-IFN compared to those treated with NAs alone[20]. Another study in Taiwan, with an average follow-up period of 6.8 years, observed a decrease in the cumulative incidence of HCC, particularly in patients with cirrhosis at baseline. However, there was no significant change in HCC incidence for patients without cirrhosis at baseline[21]. For patients with high risk factors for HCC, whether IFN therapy can achieve more benefits needs further exploration and verification. Our study focused on patients with a high risk of HCC. The 5-year cumulative incidence of HCC was 2.54% in the IFN group and 25.74% in the NAs group, and the 5-year cumulative incidence of HCC was reduced by 90.13% in the patients treated with IFN compared with NAs. To avoid the influence of previous antiviral status on the occurrence of HCC in patients, subgroup analysis was conducted between the newly treated patients and those who had been treated with NAs, and the results indicated that the cumulative incidence of HCC in 5 years was also significantly different between the two groups. In addition, stratified analysis of patients according to the five defined risk factors showed that the cumulative incidence of HCC was still significantly different between the two groups in most subgroups. The risk of HCC after IFN therapy is different in patients with and without cirrhosis compared with NAs therapy, but due to the higher overall risk in patients with cirrhosis, close monitoring is needed. In contrast, no significant difference was observed in the two subgroups with elevated AFP and imaging findings of liver nodules, which may be related to factors such as the small number of patients included in this subgroup. Alternatively, this subgroup of patients may have had other high-risk factors that had a greater impact on the development of HCC. Further more studies are needed, especially in subgroups with a low number of events (e.g., patients with abnormal AFP and patients with hepatic nodules), to confirm these outcome findings. Regardless, IFN has obvious advantages in reducing the occurrence of HCC in people at high risk of HBV-related HCC.
We focused on the high-risk population for HBV-related HCC due to the significant prevalence of HBV infection among HCC patients in China, accounting for > 80% of cases[22]. Different guidelines provide guidance on the definition of high-risk groups for HCC. Combining the guidelines of various countries and regions, it can be clearly seen that cirrhosis and HBV/hepatitis C virus infection are the most recognized risk factors for HCC[6,22-24]. In addition, genetic factors, such as having a family history of cirrhosis or HCC, greatly increase the risk of developing HCC[10,11,25]. Imaging detection of liver nodules and abnormal HCC-specific serological markers such as AFP are early warning signs of HCC worthy of special attention[26,27]. Based on these guidelines, this study proposed a definition for patients with high risk of HBV-related HCC.
Decompensated cirrhosis is a contraindication to the use of IFN; therefore, only patients with compensated cirrhosis were included in our study to reduce bias in patients with decompensated cirrhosis. Compared with the cumulative incidence of HCC after 5 years of NAs treatment, the risk of HCC in patients with a high risk of HBV-related HCC was significantly higher (25.74%) than that in ordinary CHB patients (previously reported to be 9.1%)[9]. The cumulative incidence of HCC after IFN treatment in the high-risk group of HBV-related HCC was 2.54%, demonstrating a significant reduction in HCC risk with IFN therapy.
We also analyzed the factors associated with HCC development in all patients, and univariate Cox results showed that age, family history of HCC, cirrhosis, antiviral regimen, and platelet count were associated with HCC development in patients with high risk of HBV-associated HCC. Multivariate Cox regression analysis suggested that male ≥ 40 years or female ≥ 50 years, and family history of HCC and cirrhosis were independent risk factors for HCC, which was consistent with the results of previous studies. Antiviral therapy with IFN is an effective protective factor for HCC, which confirms the conclusion that IFN can significantly reduce the cumulative incidence of HCC in patients with high risk of HBV-related HCC.
The HCC risk prediction model constructed based on patient demographic information, medical history data, and laboratory test results is a more individualized tool for evaluating HCC risk and performing risk stratification. To date, there is a variety of HCC risk prediction models for patients with different races and different etiologies of liver disease. In recent years, with the popularization of HBV antiviral therapy, a variety of HCC risk prediction models have been designed for patients with CHB treated with antiviral therapy[28,29]. Wu et al[30] conducted a systematic evaluation and external validation of 14 HCC risk prediction models. In patients with CHB, the REAL-B model, which is based on age, sex, alcohol consumption, liver cirrhosis, platelet count, diabetes and AFP, showed the best performance[15,30]. In this study, the risk stratification of HCC before and after treatment in the two groups was predicted and evaluated according to the REAL-B model. The overall risk stratification of HCC in the IFN and NAs groups was lower than before, and the difference was significant; that is, both IFN and NAs reduced the risk of HCC in patients with high risk of HBV-related HCC. Fan et al[16] developed an aMAP model involving age, male sex, albumin-bilirubin and platelet count. This model can better assess the risk of HCC in patients with chronic liver disease of different etiologies and races. According to the aMAP model, there was no significant difference in the overall HCC risk stratification in the IFN group before and after treatment, while the overall HCC risk stratification in the NAs group was higher than before treatment, and the medium-high risk stratification had a higher risk of HCC; that is, the overall HCC risk in the NAs group was higher than before. Compared with NAs therapy, IFN can delay the increase in HCC in patients with high risk of HBV-related HCC caused by aging and prolonged CHB, thus reducing the occurrence of HCC. Based on the REAL-B and aMAP models, compared with NAs, IFN can better reduce the occurrence of HCC in patients with high risk of HBV-related HCC.
This study had some limitations. Firstly, the follow-up period for most patients was limited to 5 years. The occurrence of HCC is a gradual and long-term process; therefore, it is essential to continue follow-up and analysis of patients in the future to obtain 10-year and longer-term data on the cumulative incidence of HCC. Secondly, after PSM, in both the cirrhosis and noncirrhosis subgroups, no significant difference in the 3-year and 5-year cumulative incidence of HCC was observed between the NAs and IFN groups. This may be attributed to the larger sample size, making the differences less apparent. To strengthen the findings, future research will include more patients with high risk of HBV-related HCC and continue long-term follow-up. Thirdly, since decompensated cirrhosis is an absolute contraindication to the use of IFN therapy, this study did not include patients diagnosed with decompensated cirrhosis at the beginning of the study. However, these patients may have a higher cumulative incidence of HCC, and whether IFN therapy can be used for patients with reversal to compensated cirrhosis requires further research in the future. Despite these limitations, the study provides valuable insights into the effects of IFN therapy on the occurrence of HCC in patients with high risk of HBV-related HCC. To build upon these findings and strengthen the evidence base, future studies with extended follow-up periods and inclusion of a broader range of patient populations are warranted.
In conclusion, our study demonstrates that, compared with NAs, IFN therapy can significantly reduce the occurrence of HCC in patients with high risk of HBV-related HCC.
Thanks to the patients and their families for their contribution to this study.
| 1. | Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-249. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 76817] [Cited by in RCA: 71803] [Article Influence: 14360.6] [Reference Citation Analysis (115)] |
| 2. | Xie D, Shi J, Zhou J, Fan J, Gao Q. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. Clin Mol Hepatol. 2023;29:206-216. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 139] [Cited by in RCA: 146] [Article Influence: 48.7] [Reference Citation Analysis (2)] |
| 3. | Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1323] [Reference Citation Analysis (0)] |
| 4. | Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35:2155-2166. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1057] [Cited by in RCA: 1090] [Article Influence: 99.1] [Reference Citation Analysis (35)] |
| 5. | Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33:e00046-e00019. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 457] [Cited by in RCA: 380] [Article Influence: 63.3] [Reference Citation Analysis (1)] |
| 6. | Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, Jafri W, Payawal DA, Ohki T, Ogasawara S, Chen PJ, Lesmana CRA, Lesmana LA, Gani RA, Obi S, Dokmeci AK, Sarin SK. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-370. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1808] [Cited by in RCA: 1808] [Article Influence: 200.9] [Reference Citation Analysis (23)] |
| 7. | Lin YJ, Sun FF, Zeng Z, Bi XY, Yang L, Li MH, Xie Y. Combination and Intermittent Therapy Based on Pegylated Interferon Alfa-2a for Chronic Hepatitis B with Nucleoside (Nucleotide) Analog-Experienced Resulting in Hepatitis B Surface Antigen Clearance: A Case Report. Viral Immunol. 2022;35:71-75. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 8] [Article Influence: 1.6] [Reference Citation Analysis (4)] |
| 8. | Ren P, Cao Z, Mo R, Liu Y, Chen L, Li Z, Zhou T, Lu J, Liu Y, Guo Q, Chen R, Zhou H, Xiang X, Cai W, Wang H, Bao S, Xu Y, Gui H, Xie Q. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther. 2018;18:1085-1094. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 36] [Cited by in RCA: 35] [Article Influence: 4.4] [Reference Citation Analysis (0)] |
| 9. | Sou FM, Hu TH, Hung CH, Lai HC, Wang JH, Lu SN, Peng CY, Chen CH. Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. Hepatol Int. 2020;14:513-520. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 8] [Cited by in RCA: 15] [Article Influence: 2.5] [Reference Citation Analysis (1)] |
| 10. | Huang X, Wang H, Zhang W, Gu E. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment. Eur J Gastroenterol Hepatol. 2022;34:546-552. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 3] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
| 11. | Yang Y, Wu QJ, Xie L, Chow WH, Rothman N, Li HL, Gao YT, Zheng W, Shu XO, Xiang YB. Prospective cohort studies of association between family history of liver cancer and risk of liver cancer. Int J Cancer. 2014;135:1605-1614. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 15] [Cited by in RCA: 22] [Article Influence: 1.8] [Reference Citation Analysis (2)] |
| 12. | Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 3558] [Cited by in RCA: 3413] [Article Influence: 426.6] [Reference Citation Analysis (24)] |
| 13. | Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35-S50. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1979] [Cited by in RCA: 1812] [Article Influence: 82.4] [Reference Citation Analysis (17)] |
| 14. | Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG, Jacobson IM. Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. Clin Gastroenterol Hepatol. 2022;20:1766-1775. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 52] [Cited by in RCA: 54] [Article Influence: 13.5] [Reference Citation Analysis (0)] |
| 15. | Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, Le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. J Infect Dis. 2020;221:389-399. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 67] [Cited by in RCA: 86] [Article Influence: 14.3] [Reference Citation Analysis (5)] |
| 16. | Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, Dalekos G, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen HLA, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J Hepatol. 2020;73:1368-1378. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 298] [Cited by in RCA: 306] [Article Influence: 51.0] [Reference Citation Analysis (17)] |
| 17. | Suslov A, Boldanova T, Wang X, Wieland S, Heim MH. Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver. Gastroenterology. 2018;154:1778-1790. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 162] [Cited by in RCA: 153] [Article Influence: 19.1] [Reference Citation Analysis (0)] |
| 18. | Wu ZQ, Tan L, Gan WQ, Mo ZS, Chen DB, Wang PP, Zhao QY, Xie DY, Gao ZL. The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-α. Ann Transl Med. 2021;9:414. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 9] [Reference Citation Analysis (0)] |
| 19. | Li Q, Sun B, Zhuo Y, Jiang Z, Li R, Lin C, Jin Y, Gao Y, Wang D. Interferon and interferon-stimulated genes in HBV treatment. Front Immunol. 2022;13:1034968. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 51] [Cited by in RCA: 52] [Article Influence: 13.0] [Reference Citation Analysis (3)] |
| 20. | Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT. Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. J Infect Dis. 2016;213:966-974. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 74] [Cited by in RCA: 75] [Article Influence: 7.5] [Reference Citation Analysis (8)] |
| 21. | Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007;46:45-52. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 254] [Cited by in RCA: 240] [Article Influence: 12.6] [Reference Citation Analysis (1)] |
| 22. | Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book. 2018;38:262-279. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 184] [Cited by in RCA: 175] [Article Influence: 21.9] [Reference Citation Analysis (2)] |
| 23. | Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer. 2021;10:181-223. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 566] [Cited by in RCA: 586] [Article Influence: 117.2] [Reference Citation Analysis (12)] |
| 24. | European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 6763] [Cited by in RCA: 6754] [Article Influence: 844.3] [Reference Citation Analysis (19)] |
| 25. | Chang X, Li Y, Sun C, Li X, Du W, Shang Q, Song L, Long Q, Li Q, Liu H, Wang J, Yu Z, Li J, Xiao G, Li L, Chen L, Tan L, Chen Y, Yang Y. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy. J Gastroenterol. 2023;58:481-493. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 6] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 26. | Mei Q, Yu M, Chen Q. Clinical value of contrast-enhanced ultrasound in early diagnosis of small hepatocellular carcinoma (≤ 2 cm). World J Clin Cases. 2022;10:8525-8534. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in CrossRef: 4] [Cited by in RCA: 7] [Article Influence: 1.8] [Reference Citation Analysis (0)] |
| 27. | Turshudzhyan A, Wu GY. Persistently Rising Alpha-fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Review. J Clin Transl Hepatol. 2022;10:159-163. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 33] [Cited by in RCA: 34] [Article Influence: 8.5] [Reference Citation Analysis (1)] |
| 28. | Papatheodoridis G, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol. 2016;64:800-806. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 467] [Cited by in RCA: 471] [Article Influence: 47.1] [Reference Citation Analysis (14)] |
| 29. | Hsu YC, Yip TC, Ho HJ, Wong VW, Huang YT, El-Serag HB, Lee TY, Wu MS, Lin JT, Wong GL, Wu CY. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018;69:278-285. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 133] [Cited by in RCA: 151] [Article Influence: 18.9] [Reference Citation Analysis (4)] |
| 30. | Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H, Yang HI. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clin Gastroenterol Hepatol. 2021;19:2499-2513. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 37] [Cited by in RCA: 44] [Article Influence: 8.8] [Reference Citation Analysis (1)] |